FDA extends Zevalin's indication in follicular NHL
This article was originally published in Scrip
Executive Summary
The US FDA has granted an expanded indication to Spectrum Pharmaceuticals' CD20-directed radiotherapeutic antibody Zevalin (ibritumomab tiuxetan) – for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) who achieve a partial or complete response to first-line chemotherapy.